FORT WORTH - TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company, announced today its participation in the upcoming 44th Annual International Society for Heart and Lung Transplantation (ISHLT) Meeting set for April 10-13 in Prague, Czech Republic. The company's late-breaking clinical science abstract, featuring data from its Phase 2 trial of TFF TAC, has been accepted for oral presentation.
Professor Gregory Snell, Medical Head of Lung Transplant Service at the Alfred Hospital and Lead Principal Investigator of the Phase 2 TFF TAC trial, will present the findings. The study focuses on the inhalation delivery of tacrolimus, a drug used for immunosuppression in lung transplant patients. The aim is to achieve sufficient immunosuppression while reducing systemic exposure and potential kidney toxicity compared to the oral form of the drug.
The Phase 2 trial of TFF TAC is an open-label study examining lung transplant recipients with significant renal impairment. It includes a 12-week treatment period (Part A) and an optional safety extension period (Part B). The trial's endpoints include safety, tolerability, kidney function, and prevention of acute allograft rejection.
On March 20, TFF Pharmaceuticals announced its intention to prioritize the development of TFF TAC, citing the positive interim data from the Phase 2 trial, the potential to meet a significant unmet need in lung transplant medicine, and the considerable market opportunity.
TFF Pharmaceuticals specializes in using its patented Thin Film Freezing (TFF) technology to convert various drugs into dry powder formulations, which may enhance efficacy, safety, and stability. The technology is applicable to a wide range of medications, including vaccines, small and large molecules, and biologics, for inhalation or topical delivery.
The company's statements about the potential advantages of TFF TAC and the TFF platform are forward-looking and subject to market conditions and uncertainties. The company cautions against undue reliance on these forward-looking statements and does not commit to updating them as circumstances change. This article is based on a press release statement from TFF Pharmaceuticals, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.